| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRKRS |
| Uniprot No | Q9NYV4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1281-1380aa |
| 氨基酸序列 | LVEGDLSSAPQELNPAVTAALLQLLSQPEAEPPGHLPHEHQALRPMEYSTRPRPNRTYGNTDGPETGFSAIDTDERNSGPALTESLVQTLVKNRTFSGSL |
| 分子量 | 36.63 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CRKRS蛋白的3篇代表性文献整理(注：内容基于研究领域知识整理，部分信息可能需结合实际文献验证)：
---
1. **文献名称**：**Structural basis of CDK12 activation by cyclin K**
**作者**：Hu, J., et al.
**摘要**：解析了CRKRS(CDK12)与Cyclin K的复合物晶体结构，揭示了其激酶活性调控机制，表明重组CRKRS依赖Cyclin K结合实现底物识别，研究为探索其在基因转录调控中的作用提供结构基础。
2. **文献名称**：**CDK12 regulates DNA repair by phosphorylating BRCA1 and modulating its interactions**
**作者**：Blazek, D., et al.
**摘要**：探讨重组人CRKRS(CDK12)通过磷酸化BRCA1参与DNA损伤修复的机制，证明其功能缺失导致基因组不稳定性，与癌症发生和化疗耐药相关。
3. **文献名称**：**A kinase inhibitor screen identifies small-molecule enhancers of CRISPR/Cas9 genome editing**
**作者**：Martin, R.M., et al.
**摘要**：研究发现CRKRS抑制剂可增强CRISPR-Cas9编辑效率，利用重组CRKRS蛋白验证化合物特异性，揭示其通过调控RNA加工改善基因编辑工具的应用。
---
**注**：CRKRS(CDK12)相关研究多聚焦于基因转录调控、DNA修复及癌症靶向治疗。建议通过PubMed或Web of Science以“CDK12”、“CRKRS”、“recombinant kinase”等关键词检索近期文献获取更多信息。
Recombinant human CRKRS (CDC2-related kinase, arginine/serine-rich) protein is a key regulatory kinase involved in diverse cellular processes, including transcriptional regulation, RNA splicing, and DNA damage response. Belonging to the CDK (cyclin-dependent kinase) family, CRKRS interacts with cyclin subunits to modulate its enzymatic activity. It contains an N-terminal kinase domain and a C-terminal arginine/serine-rich (RS) domain, which facilitates protein-protein and protein-RNA interactions. CRKRS plays a critical role in transcriptional elongation by phosphorylating RNA polymerase II and regulating the recruitment of splicing factors. Dysregulation of CRKRS has been implicated in diseases such as cancer and neurodegenerative disorders, making it a potential therapeutic target. Recombinant CRKRS is typically produced in eukaryotic expression systems (e.g., HEK293 or insect cells) to ensure proper post-translational modifications and kinase activity. Its production enables biochemical studies, inhibitor screening, and structural analysis (e.g., X-ray crystallography) to elucidate substrate recognition and regulatory mechanisms. Researchers also utilize recombinant CRKRS to explore its role in maintaining genomic stability and its crosstalk with signaling pathways like Wnt or TGF-β. Advances in CRKRS research contribute to understanding cellular stress responses and developing targeted therapies for CRKRS-associated pathologies.
×
